A research team at Saarland University has demonstrated in a clinical study that a widely used anti-allergy nasal spray containing the active ingredient azelastine can significantly reduce the risk of infection with the SARS-CoV-2 virus. The results of the placebo-controlled trial involving 450 healthy participants have now been published in JAMA Internal Medicine.

Professor Deng Hongkui’s team from the Peking University School of Life Sciences has made the first successful differentiation of human pluripotent stem cells into fully endocrine-subtype-complete islets.

UCLA researchers have developed a new kind of immunotherapy that uses specially engineered immune cells equipped with built-in weapons to attack kidney cancer tumors and reprogram their protective environment—all without the need to customize treatment for each individual patient.

Biomedical engineers at Duke University have successfully conducted experiments to treat damage caused by heart attacks in nonhuman primates using gene therapy for the first time.

Tuberculosis has been a scourge upon humanity throughout history. In killing more than a million each year worldwide, it remains the leading cause of death from a single infectious pathogen.

A world-first clinical trial has found that a simple daily nasal spray can significantly reduce the risk of COVID-19 in cancer patients, offering a potential new tool to protect vulnerable people from the virus.